Bronchiolitis Obliterans Syndrome

Bronchiolitis obliterans complication from allogenic HEMATOPOIETIC STEM CELL TRANSPLANTATION and LUNG TRANSPLANTATION.

Also Known As:

Bronchiolitis Obliterans Syndromes; CLAD, Obstructive; Chronic Graft Versus Host Disease; Chronic Graft-Versus-Host Diseases; Disease, Chronic Graft-Versus-Host; Graft-Versus-Host Disease, Chronic; Graft-Versus-Host Diseases, Chronic; Obstructive CLADs; Syndrome, Bronchiolitis Obliterans; BOS Bronchiolitis Obliterans Syndrome; Chronic Graft-Versus-Host Disease; Obstructive CLAD; Obstructive Chronic Lung Allograft Dysfunction

Networked: 3192 relevant articles (183 outcomes, 254 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Hematologic Neoplasms (Hematological Malignancy)
2.	Autoimmune Diseases (Autoimmune Disease)
3.	Neoplasms (Cancer)
4.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
5.	Infections

Experts

1.	Lee, Stephanie J: 68 articles (10/2022 - 04/2003)
2.	Pavletic, Steven Z: 48 articles (10/2022 - 04/2005)
3.	Ritz, Jerome: 47 articles (11/2022 - 04/2004)
4.	Antin, Joseph H: 45 articles (11/2022 - 04/2004)
5.	Blazar, Bruce R: 45 articles (10/2022 - 04/2009)
6.	Martin, Paul J: 44 articles (05/2022 - 07/2002)
7.	Flowers, Mary E D: 40 articles (11/2021 - 07/2002)
8.	Cutler, Corey: 39 articles (10/2022 - 04/2005)
9.	Soiffer, Robert J: 37 articles (11/2022 - 04/2004)
10.	Cutler, Corey S: 35 articles (11/2022 - 10/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Bronchiolitis Obliterans Syndrome:

1.	SteroidsIBA 03/01/2006 - "Although no strategy has been demonstrated to be effective in specifically preventing chronic graft-versus-host disease, several drugs have recently been demonstrated to be effective therapeutic agents for steroid-refractory disease. " 03/01/2006 - "Renewed interest and understanding of chronic graft-versus-host disease have led to novel treatment strategies for steroid-refractory disease. " 06/01/2005 - "We enrolled 25 patients with extensive, steroid-refractory chronic graft-versus-host disease (cGVHD) in a prospective trial evaluating the efficacy of extracorporeal photophoresis (ECP) in both skin and visceral cGVHD. " 10/06/2023 - "A statistically significant association was found between seizure and the HSCT type (lower risk for a related identical donor, p = .010), prophylactic or therapeutic mycophenolate use (p = .043 and .046, respectively), steroid use (p = .023), selective CD45RA+ depletion (p = .002), pre-engraftment syndrome (p = .007), and chronic graft-versus-host disease (GVHD) severity (p = .030). " 06/15/2023 - "Steroid-refractory chronic graft-versus-host disease (cGVHD) after allogeneic transplant remains a significant cause of morbidity and mortality. "
2.	Azithromycin (Zithromax)FDA LinkGeneric 06/01/2018 - "Azithromycin has been shown to be beneficial in some LTRs with bronchiolitis obliterans syndrome/OB. " 04/01/2012 - "Azithromycin is protective against the development of bronchiolitis obliterans syndrome (BOS) and reduces mortality in LTRs. " 03/01/2007 - "[Azithromycin as a novel treatment for bronchiolitis obliterans syndrome]." 02/01/2011 - "Azithromycin (AZM) improved bronchiolitis obliterans syndrome (BOS) and reduced aspiration in lung transplant (LTx) recipients. " 09/01/2005 - "Short-term improvement in lung function was observed in 5 of 6 lung transplant recipients with bronchiolitis obliterans syndrome (BOS) who were treated with oral azithromycin. "
3.	Tacrolimus (Prograf)FDA LinkGeneric 09/01/2003 - "Topical tacrolimus--a novel treatment alternative for cutaneous chronic graft-versus-host disease." 03/01/2007 - "Long-term efficacy of topical tacrolimus on oral lesions of chronic graft-versus-host disease." 06/01/2009 - "Pooled analysis showed a trend toward a lower risk of bronchiolitis obliterans syndrome (BOS) among tacrolimus-treated patients, although it did not reach significances (OR, 0.53; 95% CI, 0.25-1.12; P = .10). " 01/01/2005 - "Topical tacrolimus in severe chronic graft-versus-host disease." 04/01/2003 - "This points to a chronic graft-versus-host disease (cGvHD)-like syndrome linked to tacrolimus. "
4.	Rituximab (Mabthera)FDA Link 01/15/2002 - "Treatment with Rituximab resulted in a complete remission in all patients without signs of or progression of bronchiolitis obliterans syndrome. " 09/01/2011 - "The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study." 11/01/2008 - "In addition, various studies have observed significant improvements in chronic graft-versus-host disease using the anti-CD20(+) antibody rituximab. " 12/01/2019 - "We suggested that delayed B cell recovery was caused by chronic graft-versus-host disease (GVHD) related drugs, not rituximab administration. " 10/01/2019 - "Long-term follow-up of rituximab in treatment of chronic graft-versus-host disease-single center experience."
5.	Monoclonal AntibodiesIBA 01/01/2018 - "Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease." 08/01/2011 - "[Use of monoclonal antibodies in prophylaxis and treatment of acute and chronic graft-versus-host disease in 2011]." 08/01/2003 - "Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody." 12/01/2022 - "Humanized anti-IL-26 monoclonal antibody as a novel targeted therapy for chronic graft-versus-host disease." 10/15/2004 - "Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease."
6.	Cyclosporine (Ciclosporin)FDA LinkGeneric 03/20/2021 - "She developed chronic graft-versus-host disease manifesting as pulmonary complications and was administered cyclosporine. " 01/13/2015 - "Leucocytosis (>100×10(9)/L), high-risk AML and cyclosporine A concentration under 200 µg/L were correlated with high relapsing rates while CMV reaction and chronic graft versus host disease had a low relapsing rate. " 08/01/2012 - "She developed chronic graft-versus-host disease, and cyclosporine (CSA) was continued until 17 months after HSCT. " 02/28/2006 - "Seven patients came down with LONIPC during fast tapering of cyclosporine A prophylaxis and 15 patients had already chronic graft versus host disease (cGVHD) before the occurrence of respiratory symptoms. " 12/15/2001 - "Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial."
7.	ruxolitinibIBA 01/01/2020 - "Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69.5% and 57.1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients." 12/01/2021 - "Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice-a prospective single-center trial." 01/01/2021 - "This study aimed to evaluate the effectiveness of Ruxolitinib for acute/chronic graft-versus-host disease in children. " 01/01/2020 - "Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study." 01/01/2022 - "Ruxolitinib, a JAK1/2 inhibitor, is used to treat chronic graft versus host disease (cGVHD) in adult allogeneic hematopoietic stem cell transplant patients, but experience in children is limited, perhaps because of lack of pediatric dosing information. "
8.	Imatinib Mesylate (Gleevec)FDA Link 01/01/2010 - "First clinical case studies demonstrated anti-fibrotic effects of imatinib in selected patients with SSc and other fibrotic diseases, and observational studies in sclerotic chronic graft-versus-host disease showed promising results. " 10/22/2009 - "Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease." 12/01/2023 - "The biological activities of imatinib and VISTA agonist M351-0056 were studied in monocytes and T cells and in lupus-like disease murine model of chronic graft-versus-host disease (cGVHD) and lupus-prone MRL/lpr mice. " 11/26/2020 - "Loading Imatinib inside targeted nanoparticles to prevent Bronchiolitis Obliterans Syndrome." 08/01/2020 - "Motor ability, function, and health-related quality of life as correlates of symptom burden in patients with sclerotic chronic graft-versus-host disease receiving imatinib mesylate."
9.	ibrutinibIBA 01/01/2015 - "Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice." 01/01/2023 - "Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study." 11/01/2014 - "Ibrutinib treatment ameliorates murine chronic graft-versus-host disease." 11/01/2022 - "Ibrutinib Treatment of Pediatric Chronic Graft-versus-Host Disease: Primary Results from the Phase 1/2 iMAGINE Study." 01/01/2023 - "The population pharmacokinetic (PK) and exposure-response (E-R) analyses for the safety of ibrutinib for the treatment of chronic graft-versus-host disease (cGVHD) is presented. "
10.	Thalidomide (Thalomid)FDA Link 11/01/1995 - "Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD). " 01/01/1995 - "We describe a protocol for monitoring patients treated with thalidomide which permits convenient transportation and storage of specimens and report, provisionally, that plasma concentrations in the range 1-7 mg/L are therapeutically effective in chronic graft-versus-host disease without adverse side effects." 04/01/2003 - "Studies of thalidomide in chronic graft-versus-host disease showed benefit in children and adults as treatment, but not as prophylaxis. " 10/01/1998 - "(6) In the curative treatment of chronic graft-versus-host disease in bone marrow graft recipients, thalidomide has been assessed only in non comparative trials involving a few dozens of patients." 01/01/2018 - "Stromal progenitor cell modulation by thalidomide in the treatment of oral chronic graft-versus-host disease."

Therapies and Procedures

1.	Hematopoietic Stem Cell Transplantation 01/01/2016 - "Although mesenchymal stromal cells (MSCs) possess immunomodulatory properties and exhibit promising efficacy against chronic graft-versus-host disease (cGVHD), little is known about the efficacy of MSCs in the prophylaxis of cGVHD after HLA-haploidentical hematopoietic stem-cell transplantation (HLA-haplo HSCT). " 01/01/2019 - "Although peripheral blood stem cells (PBSC) have worldwide become the predominant source of progenitor cells for hematopoietic stem cell transplantation (HSCT), debate about their role compared with bone marrow (BM) has recently intensified, in large part based on the results of a multicenter Clinical Trials Network study which showed lower incidence of chronic graft-versus-host disease (cGVHD) and improved quality of life in recipients of myeloablative HLA-matched unrelated BM compared with PBSC transplants. " 01/01/2023 - "Evaluation of safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells in pediatric bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)." 01/01/2021 - "The efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is limited by the occurrence of acute and chronic graft-versus-host disease (GVHD). " 11/25/2020 - "The efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is limited by acute and chronic graft-versus-host disease (GVHD). "
2.	Photopheresis 03/01/2016 - "Extracorporeal photopheresis is an effective treatment for acute and chronic graft versus host disease without severe impairment of the recipient's immune system. " 10/01/2013 - "Extracorporeal photopheresis (ECP) is an effective treatment for both acute and chronic graft-versus-host disease (GVHD) in children and adults. " 01/01/2018 - "Extracorporeal Photopheresis: An Efficacious and Well-Tolerated Treatment for Cutaneous and Oral Mucosal Chronic Graft-versus-Host Disease." 12/01/2011 - "Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study." 05/01/1999 - "The aim of our study was to assess the efficacy of extracorporeal photopheresis (ECP) in chronic graft-versus-host disease (GVHD). "
3.	Transplantation 10/01/2019 - "Donor lymphocyte infusion (DLI) at an early stage of post-transplantation resulted in complete molecular remission for 29 months with durable chronic graft-versus-host disease. " 01/01/2018 - "Longer remission after first transplantation (P<0.001), complete remission at second transplant (P=0.008), no prior chronic graft-versus-host disease (P<0.001) and change to a new donor (P=0.04) predicted better outcome. " 02/01/2004 - "Twenty-three months after transplantation, the child is in continuous complete remission and has full donor chimerism and no signs of chronic graft-versus-host disease." 08/01/2003 - "Conditioning and the period after transplantation were uneventful, complete donor chimerism was achieved and the patient continues to be in molecular remission without significant chronic graft-versus-host disease. " 02/01/1991 - "Neither the percentages nor the absolute numbers of host PBMC or GRAN were significantly affected by HLA-matching, TBI dose-intensity, pretransplant remission status, subsequent development of acute or chronic graft-versus-host disease or relapse after transplantation. "
4.	Lung Transplantation 10/01/2014 - "Likewise, in lung transplantation, oversized donor lungs have been linked to higher expiratory airflows, lower risk of bronchiolitis obliterans syndrome, and improved survival. " 04/01/2010 - "Lung transplantation frequently offers a major improvement in quality of life; however, long-term survival is often limited by the development of the bronchiolitis obliterans syndrome, which is the equivalent of a chronic pulmonary graft rejection. " 01/27/2012 - "Genetic polymorphisms and bronchiolitis obliterans syndrome after lung transplantation: promising results and recommendations for the future." 03/01/2002 - "No current evidence demonstrates improved survival or decreased rate of bronchiolitis obliterans syndrome (BOS) despite regularly scheduled fiberoptic bronchoscopy (FOB) with transbronchial biopsy and bronchoalveolar lavage (TBB/BAL) after lung transplantation. " 11/01/2019 - "In this large-scale national registry study, we aimed to investigate whether survival and the rates of bronchiolitis obliterans syndrome (BOS) and coronary allograft vasculopathy (CAV) are affected by simultaneous heart and/or lung transplantation (HLTx). "
5.	Therapeutics 09/15/2005 - "Half of the patients with chronic graft-versus-host disease (GvHD) do not achieve a complete remission with first-line therapy. " 10/28/2023 - "A novel approach to visualize clinical benefit of therapies for chronic graft versus host disease (cGvHD): the probability of being in response (PBR) applied to the REACH3 study." 01/01/2017 - "Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: A phase I/II study." 07/01/2015 - "The 2006 National Institutes of Health (NIH) Consensus paper presented recommendations by the Ancillary Therapy and Supportive Care Working Group to support clinical research trials in chronic graft-versus-host disease (GVHD). " 07/01/2015 - "National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report."